Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.53 |
| ▸ | RXRA | P19793 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653162 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL764389 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL16188440 | 0.87 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653157 | 0.86 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13653161 | 0.86 | PPARG (0.55) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL13875306 | 0.85 | PPARG (0.60) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL11882623 | 0.84 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL10280515 | 0.84 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL11882613 | 0.84 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL25300796 | 0.83 | PPARG (0.61) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237787-A1 | Anti-Inflammatory Compounds and Uses Thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20120316139-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | MEDICON PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| US-20100217028-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2010-08-26 | — | — | US | disclosed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237787-A1 | Anti-Inflammatory Compounds and Uses Thereof | TNF, NFKBIA, IL6 | PPARG 70/4885RXRA 1124/4885CYP1A2 647/4885 |
| US-20120316139-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | NFKBIA, TNF, MPO | PPARG 80/4885RXRA 774/4885CYP1A2 659/4885 |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | PPARG 534/4885RXRA 357/4885CYP1A2 48/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | PPARG 537/4885RXRA 303/4885CYP1A2 27/4885 |
| US-20100217028-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | CYP2A13, CYP3A43, POR | PPARG 813/4885RXRA 720/4885CYP1A2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.